Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
13
×
cancer
13
×
life sciences
national blog main
national top stories
roche
13
×
boston blog main
boston top stories
san francisco blog main
san francisco top stories
national
indiana blog main
indiana top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
new york top stories
pfizer
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
deals
investing
novartis
amgen
bristol-myers squibb
fda
cancer immunotherapy
genentech
immunotherapy
What
cancer
drug
roundup
annual
bio
society
clinical
conference
latest
medical
oncology
ahead
american
asco
ash
blood
crispr
days
esmo
european
fda
focus
gene
ipo
medicines
meeting
plan
therapy
today
access
acquire
address
advanced
advantages
agreed
alliance
alzheimer’s
ambien
approval
approves
Language
unset
Current search:
biotech
×
cancer
×
roche
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More